A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2019-02-21
Target enrollment:
Participant gender:
Summary
The trial is an open label Simon optimal two-stage Phase II trial of fixed doses of oral
meloxicam and subcutaneous filgrastim to assess the safety and efficacy in mobilizing
autologous peripheral blood stem cells (PBSC) from multiple myeloma (MM) and non-Hodgkin's
lymphoma (NHL) patients planning to undergo high-dose chemotherapy with stem cell support.
Clinical data regarding the cellular composition and function of the graft mobilized by this
combination will be obtained.